CITIC guojiantrazumab is expected to be approved within this year
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the website of the State Food and Drug Administration (CFDA) on April 15, the heavy-duty class 2 biological products "recombinant anti HER2 humanized monoclonal antibody for injection" (trastuzumab), which is under research by China CITIC, the leading domestic monoclonal antibody enterprise, will enter the site for inspection If all goes well, it is expected to be approved for production within this year Lansheng shares directly and indirectly hold about 15% equity of CITIC Guojian This product is the original research drug of Roche pharmaceutical in Switzerland Its trade name is Herceptin In 2011, its global sales reached US $5.9 billion The cost of a course of treatment is about US $32000, and the cost of treatment is extremely high.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
